特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
971218

マイコプラズマ検査の世界市場 (~2025年):製品&サービス (アッセイ/キット/試薬)・技術 (NAT・ELISA・染色)・用途 (細胞株・EPC)・エンドユーザー (バイオ医薬品・細胞バンク・CRO)・地域別

Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 150 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
マイコプラズマ検査の世界市場 (~2025年):製品&サービス (アッセイ/キット/試薬)・技術 (NAT・ELISA・染色)・用途 (細胞株・EPC)・エンドユーザー (バイオ医薬品・細胞バンク・CRO)・地域別
出版日: 2020年11月11日
発行: MarketsandMarkets
ページ情報: 英文 150 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のマイコプラズマ検査の市場規模は予測期間中9.7%のCAGRで推移し、2020年の6億8900万米ドルから、2025年には10億9500万米ドルの規模に成長すると予測されています。細胞培養汚染に対する懸念の高まり、製薬およびバイオテクノロジー産業の成長、製薬部門におけるR&Dおよび投資の増加などの要因が同市場の成長を推進しています。

製品・サービス区分別では、アッセイ・キット・試薬の部門が予測期間中最大の成長を示すと予測されています。また、用途別では、細胞株試験の部門が最大のCAGRを示す見通しです。バイオ医薬品産業の急速な成長、モノクローナル抗体への需要の増加などの要因が同部門の成長を後押ししています。さらに、地域別では、アジア太平洋地域が期間中最大のCAGRを示すと予測されています。主要企業による新興諸国への拡張、ライフサイエンス研究に対する支出の増加、インドや中国などへの医薬品アウトソーシングの増加などの要因が同地域の成長を牽引する見通しです。

当レポートでは、世界のマイコプラズマ検査の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品&サービス・技術・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 市場機会
    • 課題
  • COVID-19の影響
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析

第6章 市場分析・予測:製品・サービス別

  • アッセイ・キット・試薬
    • NATアッセイ・キット・試薬
    • ELISAアッセイ・キット・試薬
    • 除去キット
    • 染色キット
    • その他
  • 機器
  • サービス

第7章 市場分析・予測:技術別

  • NAT
  • ELISA
  • 染色
  • その他

第8章 市場分析・予測:用途別

  • 細胞株検査
  • ウイルス検査
  • EPC (End of Production Cell) 検査

第9章 市場分析・予測:エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • CRO
  • 学術・研究機関
  • 細胞バンク&ラボ

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他
  • その他の地域

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 企業評価クアドラント
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • MERCK KGAA
    • ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE LTD.)
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • LONZA GROUP LTD.
    • THERMO FISHER SCIENTIFIC, INC.
    • EUROFINS SCIENTIFIC GROUP
    • SARTORIUS STEDIM BIOTECH S.A.
    • AGILENT TECHNOLOGIES, INC.
    • MERIDIAN BIOSCIENCE, INC.
    • AMERICAN TYPE CULTURE COLLECTION
  • その他の企業
    • BIONIQUE TESTING LABORATORIES, INC.
    • INVIVOGEN
    • PROMOCELL GMBH
    • BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD.
    • CLONGEN LABORATORIES, LLC.
    • CREATIVE BIOARRAY
    • NELSON LABORATORIES FAIRFIELD, INC. (A PART OF SOTERA HEALTH)
    • NORGEN BIOTEK CORPORATION
    • BIOTOOLS B & M LABS, S.A.
    • GENBIO (A PART OF EXONHIT THERAPEUTICS SA)
    • GENECOPOEIA, INC.
    • MINERVA BIOLABS GMBH
    • MYCOPLASMA EXPERIENCE
    • SAVYON DIAGNOSTICS
    • SCIENCELL RESEARCH LABORATORIES

第13章 付録

目次
Product Code: BT 3371

The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global mycoplasma testing industry's growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.

"The assays, kits, & reagents segment accounted for the highest growth rate in the mycoplasma testing market, by product, during the forecast period "

The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this market's largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the important factors driving the growth of this market segment.

"Cell line testing segment accounted for the highest CAGR"

Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segment's growth.

"Asia Pacific: The fastest-growing region mycoplasma testing market"

The Asia Pacific mycoplasma testing market is estimated to grow at the highest CAGR during the forecast period. This can primarily be attributed to the expansion of key market players in emerging Asian countries, increasing expenditure on life science research in the region, and the increasing trend of pharmaceutical outsourcing to Asian countries such as India and China.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World - 12%

List of companies profiled in the report:

  • Thermo Fisher Scientific, Inc. (US)
  • Charles River Laboratories International, Inc. (US)
  • Lonza Group Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Roche Diagnostics (Switzerland)
  • American Type Culture Collection (US)
  • Bionique Testing Laboratories, Inc. (US)
  • InvivoGen (US)
  • PromoCell GmbH (Germany),
  • Biological Industries Israel Beit Haemek Ltd. (Israel)
  • Creative Bioarray (US)
  • Mycoplasma Experience (UK)
  • Norgen Biotek Corp. (Canada)
  • Agilent Technologies (US)
  • Biotools B & M Labs, S.A. (Spain)
  • Eurofins Scientific (Luxembourg)
  • GeneCopoeia, Inc. (US)
  • GenBio (Canada)
  • Minerva Biolabs GmbH (Germany)
  • Meridian Bioscience, Inc. (US)
  • Sartorius AG (Germany)
  • Savyon Diagnostics (Israel)
  • Nelson Laboratories Fairfield, Inc. (US)
  • Clongen Laboratories, LLC (US)
  • ScienCell Research Laboratories, Inc. (Canada).

Research Coverage:

This report provides a detailed picture of the global mycoplasma testing market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technique, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mycoplasma testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and trends.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • FIGURE 1 INCLUSIONS & EXCLUSIONS
    • 1.2.1 MARKETS COVERED
    • FIGURE 2 MYCOPLASMA TESTING MARKET SEGMENTATION
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 5 MYCOPLASMA TESTING MARKET: BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 6 MYCOPLASMA TESTING MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 8 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 9 MYCOPLASMA TESTING MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
    • FIGURE 10 MYCOPLASMA TESTING MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    • FIGURE 11 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 MYCOPLASMA TESTING MARKET OVERVIEW
    • FIGURE 12 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
  • 4.2 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 13 NAT ASSAYS, KITS, & REAGENTS SEGMENT TO COMMAND THE LARGEST MARKET SHARE IN 2019
  • 4.3 MYCOPLASMA TESTING MARKET, BY TECHNIQUE, 2020 VS. 2025
    • FIGURE 14 GROWING ADOPTION OF NAT IN EMERGING ECONOMIES TO DRIVE MARKET GROWTH
  • 4.4 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025
    • FIGURE 15 ASIA PACIFIC MARKET TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 MYCOPLASMA TESTING MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing concerns over cell culture contamination
      • 5.2.1.2 Growth in pharmaceutical and biotechnology industries
    • TABLE 1 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019-2020
      • 5.2.1.3 Rising pharmaceutical R&D activities and investments
    • FIGURE 17 INCIDENCE OF THE TOP 10 FATAL CONDITIONS GLOBALLY, 2019 (%)
    • TABLE 2 RISING CANCER INCIDENCE, BY COUNTRY/REGION, 2018 VS. 2025
    • FIGURE 18 R&D SPENDING BY PHRMA MEMBER-COMPANIES, 2001-2019 (USD BILLION)
    • TABLE 3 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2018
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing
      • 5.2.2.2 Emerging economies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 High degree of consolidation acts as an entry barrier for new entrants
  • 5.3 IMPACT OF COVID-19 ON THE MYCOPLASMA TESTING MARKET
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET
    • FIGURE 20 RESTRAINTS IN THE VALUE CHAIN, BY STAGE
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 21 SUPPLY CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 22 ECOSYSTEM ANALYSIS OF THE MYCOPLASMA TESTING MARKET

6 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 4 AVERAGE SELLING PRICE
    • TABLE 5 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
  • 6.2 ASSAYS, KITS, & REAGENTS
    • 6.2.1 INCREASING ADOPTION OF NAT TO DRIVE MARKET GROWTH
    • TABLE 6 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 7 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.2.2 NAT ASSAYS, KITS, & REAGENTS
    • TABLE 8 NAT ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.2.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS
    • TABLE 9 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.2.4 ELIMINATION KITS
    • TABLE 10 ELIMINATION KITS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.2.5 STAINS
    • TABLE 11 MYCOPLASMA TESTING STAINS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.2.6 OTHER ASSAYS, KITS, & REAGENTS
    • TABLE 12 OTHER ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 DEMAND FOR FULLY AUTOMATED INSTRUMENTS IS INCREASING IN RESEARCH APPLICATIONS
    • TABLE 13 MYCOPLASMA TESTING INSTRUMENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 6.4 SERVICES
    • 6.4.1 LACK OF INFRASTRUCTURE AND EXPERTISE HAVE DRIVEN RELIANCE ON SERVICE PROVIDERS
    • TABLE 14 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)

7 MYCOPLASMA TESTING MARKET, BY TECHNIQUE

  • 7.1 INTRODUCTION
    • TABLE 15 MYCOPLASMA TESTING MARKET, BY TECHNIQUE, 2018-2025 (USD MILLION)
  • 7.2 NUCLEIC ACID TESTING
    • 7.2.1 NAT SEGMENT DOMINATED THE MARKET IN 2019
    • TABLE 16 NAT-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
    • 7.3.1 ELISA IS WIDELY USED FOR MYCOPLASMA DETECTION IN RESEARCH APPLICATIONS
    • TABLE 17 ELISA-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 7.4 STAINING
    • 7.4.1 STAINING OF CULTURES CAN PROVIDE RAPID RESULTS
    • TABLE 18 STAINING-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 7.5 OTHER TECHNIQUES
    • TABLE 19 OTHER TECHNIQUES-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)

8 MYCOPLASMA TESTING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 20 MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 8.2 CELL LINE TESTING
    • 8.2.1 RAPID GROWTH IN THE BIOPHARMACEUTICAL INDUSTRY TO DRIVE THE DEMAND FOR CELL LINE TESTING
    • TABLE 21 MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 22 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 23 EUROPE: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.3 VIRUS TESTING
    • 8.3.1 RISING DEMAND FOR VACCINES TO DRIVE MARKET GROWTH
    • TABLE 25 KEY VIRUS TESTING PRODUCTS/SERVICES OFFERED BY MARKET PLAYERS
    • TABLE 26 MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 27 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 28 EUROPE: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.4 END-OF-PRODUCTION CELL TESTING
    • 8.4.1 GROWING DEMAND FOR BIOLOGICS TO DRIVE MARKET GROWTH
    • TABLE 30 MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 31 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 32 EUROPE: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018-2025 (USD MILLION)

9 MYCOPLASMA TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 34 MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES FORM THE LARGEST END-USER SEGMENT IN THE MYCOPLASMA TESTING MARKET
    • FIGURE 23 R&D INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY, 2012-2026 (USD BILLION)
    • TABLE 35 PHARMACEUTICAL PATENT GRANTS, 2017 VS. 2019, BY COUNTRY
    • TABLE 36 MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2025 (USD MILLION)
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 GROWTH IN OUTSOURCING TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
    • TABLE 37 MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2025 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 ACADEMIC AND RESEARCH INSTITUTES PROVIDE VARIOUS MICROBIOLOGY TESTING SERVICES
    • TABLE 38 MYCOPLASMA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2025 (USD MILLION)
  • 9.5 CELL BANKS & LABORATORIES
    • 9.5.1 IT IS ESTIMATED THAT ABOUT 5-30% OF THE WORLD'S CELL LINES ARE CONTAMINATED WITH MYCOPLASMAS
    • TABLE 39 MYCOPLASMA TESTING MARKET FOR CELL BANKS & LABORATORIES, BY REGION, 2018-2025 (USD MILLION)

10 MYCOPLASMA TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 40 MYCOPLASMA TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: MYCOPLASMA TESTING MARKET SNAPSHOT
    • TABLE 41 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 42 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 44 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 45 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 US is the largest market for mycoplasma testing products and services in North America
    • TABLE 46 US: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 47 US: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 48 US: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 49 US: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing pharma and biotech R&D investments to drive market growth
    • TABLE 50 CANADA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 51 CANADA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 52 CANADA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 53 CANADA: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 54 EUROPE: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 55 EUROPE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 56 EUROPE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 57 EUROPE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 58 EUROPE: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany accounted for the largest share of the European market in 2019
    • TABLE 59 GERMANY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 60 GERMANY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 61 GERMANY: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 62 GERMANY: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Growth in the life science industry to support market growth in the UK
    • TABLE 63 UK: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 64 UK: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 65 UK: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 66 UK: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing investments in life science R&D to support market growth in France
    • TABLE 67 FRANCE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 68 FRANCE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 69 FRANCE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 70 FRANCE: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Italy is one of the leaders in life science research in Europe
    • TABLE 71 ITALY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 72 ITALY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 73 ITALY: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 74 ITALY: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Increasing opportunities for generics and biosimilars manufacturers to support market growth in Spain
    • TABLE 75 SPAIN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 76 SPAIN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 77 SPAIN: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 78 SPAIN: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 79 ROE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 80 ROE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 81 ROE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 82 ROE: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 25 APAC: MYCOPLASMA TESTING MARKET SNAPSHOT
    • TABLE 83 APAC: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 84 APAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 85 APAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 86 APAC: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 87 APAC: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 China accounted for the largest share of the APAC market in 2019
    • TABLE 88 CHINA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 89 CHINA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 90 CHINA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 91 CHINA: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Increasing demand for technologically advanced research products to drive market growth in Japan
    • TABLE 92 JAPAN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 93 JAPAN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 94 JAPAN: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 95 JAPAN: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Growing CRO base in India to support market growth
    • TABLE 96 INDIA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 97 INDIA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 98 INDIA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 99 INDIA: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 100 ROAPAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 101 ROAPAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 102 ROAPAC: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 103 ROAPAC: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 104 ROW: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 105 ROW: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 106 ROW: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 107 ROW: MYCOPLASMA TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
    • FIGURE 26 KEY DEVELOPMENTS IN THE MYCOPLASMA TESTING MARKET (JANUARY 2017-SEPTEMBER 2020)
  • 11.2 MYCOPLASMA TESTING MARKET SHARE ANALYSIS
    • FIGURE 27 MYCOPLASMA TESTING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
  • 11.3 COMPANY EVALUATION QUADRANT
    • 11.3.1 DEFINITION AND METHODOLOGY
    • 11.3.2 VENDOR DIVE OVERVIEW
      • 11.3.2.1 Stars
      • 11.3.2.2 Emerging leaders
      • 11.3.2.3 Pervasive
      • 11.3.2.4 Participants
    • FIGURE 28 MYCOPLASMA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
  • 11.4 COMPETITIVE SCENARIO
    • 11.4.1 PRODUCT/SERVICE LAUNCHES
    • TABLE 108 PRODUCT/SERVICE LAUNCHES & REGULATORY APPROVALS (JANUARY 2017-SEPTEMBER 2020)
    • 11.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • TABLE 109 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (JANUARY 2017-SEPTEMBER 2020)
    • 11.4.3 ACQUISITIONS
    • TABLE 110 ACQUISITIONS (JANUARY 2017-SEPTEMBER 2020)
    • 11.4.4 EXPANSIONS
    • TABLE 111 EXPANSIONS (JANUARY 2017-SEPTEMBER 2020)

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS

(Business overview, Products offered, Recent developments, MNM view)**

    • 12.1.1 MERCK KGAA
    • FIGURE 29 MERCK KGAA: COMPANY SNAPSHOT (2019)
    • 12.1.2 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE LTD.)
    • FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
    • 12.1.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • FIGURE 31 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019)
    • 12.1.4 LONZA GROUP LTD.
    • FIGURE 32 LONZA GROUP LTD.: COMPANY SNAPSHOT (2019)
    • 12.1.5 THERMO FISHER SCIENTIFIC, INC.
    • FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
    • 12.1.6 EUROFINS SCIENTIFIC GROUP
    • FIGURE 34 EUROFINS SCIENTIFIC GROUP: COMPANY SNAPSHOT (2019)
    • 12.1.7 SARTORIUS STEDIM BIOTECH S.A.
    • FIGURE 35 SARTORIUS STEDIM BIOTECH S.A.: COMPANY SNAPSHOT (2019)
    • 12.1.8 AGILENT TECHNOLOGIES, INC.
    • FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
    • 12.1.9 MERIDIAN BIOSCIENCE, INC.
    • FIGURE 37 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2019)
    • 12.1.10 AMERICAN TYPE CULTURE COLLECTION
  • 12.2 OTHER PLAYERS
    • 12.2.1 BIONIQUE TESTING LABORATORIES, INC.
    • 12.2.2 INVIVOGEN
    • 12.2.3 PROMOCELL GMBH
    • 12.2.4 BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD.
    • 12.2.5 CLONGEN LABORATORIES, LLC.
    • 12.2.6 CREATIVE BIOARRAY
    • 12.2.7 NELSON LABORATORIES FAIRFIELD, INC. (A PART OF SOTERA HEALTH)
    • 12.2.8 NORGEN BIOTEK CORPORATION
    • 12.2.9 BIOTOOLS B & M LABS, S.A.
    • 12.2.10 GENBIO (A PART OF EXONHIT THERAPEUTICS SA)
    • 12.2.11 GENECOPOEIA, INC.
    • 12.2.12 MINERVA BIOLABS GMBH
    • 12.2.13 MYCOPLASMA EXPERIENCE
    • 12.2.14 SAVYON DIAGNOSTICS
    • 12.2.15 SCIENCELL RESEARCH LABORATORIES

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.